<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543788</url>
  </required_header>
  <id_info>
    <org_study_id>2014.850</org_study_id>
    <nct_id>NCT02543788</nct_id>
  </id_info>
  <brief_title>CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS</brief_title>
  <official_title>CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS: DEMYELINATING AND/OR PRIMARY DEGENERATIVE PATHOPHYSIOLOGY?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation pour la Recherche Médicale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that&#xD;
      may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any&#xD;
      acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and&#xD;
      P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be&#xD;
      secondary to retrograde atrophy of axons within plaques of demyelination or a primary&#xD;
      progressive degeneration of ganglion cells, but the underlying physiopathology has not been&#xD;
      fully questioned in the different profile types of CON.&#xD;
&#xD;
      In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON,&#xD;
      i.e. secondary to demyelination or primary degeneration, in patients complaining of&#xD;
      persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to&#xD;
      moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive&#xD;
      neuro-ophthalmological assessment including clinical examination, visual evoked potentials&#xD;
      (pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT&#xD;
      (peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In&#xD;
      these patients with mild to moderate CON, investigators aim at differentiating patients&#xD;
      showing predominant demyelination from those showing pure or predominant axonal degeneration.&#xD;
      Visual function assessment and degree of axonal degeneration will be compared and correlated&#xD;
      in the two types of underlying pathophysiology and in the group of control subject. In a&#xD;
      following longitudinal study, the patients will be re-assessed a year later in order to&#xD;
      evaluate the progression of CON in both profile types. Our hypothesis would be that visual&#xD;
      function and progression is worse in the degeneration group as compared to the demyelination&#xD;
      group. This study should help to find reliable measures of the pathophysiology of CON and&#xD;
      correlate it with the long-term visual prognostic of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Day0 15' P100 VEP latency at one year</measure>
    <time_frame>D0 and one year</time_frame>
    <description>15' VEP latency may be the best outcome that allow differentiating patients from controls, and each of the sub-group of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Day0 100%, 2.5% and 1.25% ETDRS Visual Acuity at one year (composite measure)</measure>
    <time_frame>D0 and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day0 Visual field macular threshold and corrected mean visual field deficit at one year (composite measure)</measure>
    <time_frame>D0 and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change frome Day0 NEI-VFQ 25 composite score and 10-item score at one year (composite measure)</measure>
    <time_frame>D0 and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day0 N75, P100, N135 VEP latency and amplitude; P50, N95 ERG latency and amplitude; p1 mERG latency and amplitude at one year (composite measure)</measure>
    <time_frame>D0 and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day0 OCT peripapillary RNLF thickness and Ganglion cell layer average thickness on macular dense volume at one year (composite measure)</measure>
    <time_frame>D0 and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI presence or absence of optic nerve inflammatory signs on diameter of the optic nerve</measure>
    <time_frame>D0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Chronic Optic Neuropathy in Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with chronic optic neuropathy in multiple sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for patients&#xD;
&#xD;
               -  All patients may have a clinically definite, laboratory-supported diagnosis of&#xD;
                  multiple sclerosis according to the Mac Donald criteria (2010).&#xD;
&#xD;
               -  All patients may present a chronic visual complaint.&#xD;
&#xD;
               -  All patients may present mild to moderate chronic optic neuropathy (cf infra)&#xD;
&#xD;
               -  All patients may not have recent acute optic neuritis (&lt;2 years)&#xD;
&#xD;
               -  All patients will be informed about the design and purpose of the study, and all&#xD;
                  will give their informed, written consent to the protocol, which may have been&#xD;
                  approved by the local ethics committee.&#xD;
&#xD;
               -  Age: &gt; 18&#xD;
&#xD;
               -  Able to understand the instructions&#xD;
&#xD;
               -  Having a health coverage&#xD;
&#xD;
               -  Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic&#xD;
                  neuropathy&#xD;
&#xD;
        For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria:&#xD;
&#xD;
          1. Far Visual Acuity (ETDRS charts, 100% contrast) &lt; 85 letters&#xD;
&#xD;
          2. Far Visual Acuity (ETDRS charts, 2.5% contrast) &lt; 60 letters&#xD;
&#xD;
          3. Mean visual field defect on static perimetry&gt; 2dB&#xD;
&#xD;
          4. Mean pRNFL in OCT &lt; 80 µ.&#xD;
&#xD;
          5. Color vision score &gt; 35&#xD;
&#xD;
          6. Disc pallor Diagnosis of mild to moderate optic neuropathy&#xD;
&#xD;
               -  Far Visual Acuity (ETDRS charts, 100% contrast) &gt;70 letters Diagnosis of chronic&#xD;
                  optic neuropathy&#xD;
&#xD;
               -  Stable or worsening of visual acuity, visual field and/or RNFL in OCT, at 6 month&#xD;
                  of interval&#xD;
&#xD;
                  - Inclusion criteria for controls&#xD;
&#xD;
               -  Age &gt; 18 years&#xD;
&#xD;
               -  Visual acuity score (ETDRS) &gt; 85&#xD;
&#xD;
               -  Able to understand the instructions&#xD;
&#xD;
               -  Having a health coverage&#xD;
&#xD;
               -  Informed and consenting to give his written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non inclusion criteria for patients.&#xD;
&#xD;
               -  Ophthalmological&#xD;
&#xD;
                    -  Other ophthalmological disorder that could impair corrected visual acuity&#xD;
                       (Maculopathy, Retinopathy…)&#xD;
&#xD;
                    -  Ocular instability in primary position of gaze&#xD;
&#xD;
               -  Neurological&#xD;
&#xD;
                    -  Ongoing seizure&#xD;
&#xD;
                    -  Severe handicap that does not allow sitting down position for 1 hour&#xD;
&#xD;
               -  General&#xD;
&#xD;
                    -  Unstable medical state&#xD;
&#xD;
                    -  Severe renal insufficiency&#xD;
&#xD;
                    -  Allergy to gadolinium&#xD;
&#xD;
                    -  Claustrophobia&#xD;
&#xD;
                    -  Implanted electrical stimulator (pace maker)&#xD;
&#xD;
                    -  Metallic prosthesis or orthesis, cochlear implants&#xD;
&#xD;
                    -  Intraocular foreign material&#xD;
&#xD;
               -  Pregnancy (on questioning)&#xD;
&#xD;
               -  Tutelage or any legal protection measure&#xD;
&#xD;
          -  Non inclusion criteria for controls&#xD;
&#xD;
               -  Any ophthalmological disorder that could impair corrected visual acuity&#xD;
&#xD;
               -  Any neurological disorder&#xD;
&#xD;
               -  MRI contraindication&#xD;
&#xD;
               -  Allergy to gadolinium&#xD;
&#xD;
               -  Severe renal insufficiency&#xD;
&#xD;
               -  Claustrophobia&#xD;
&#xD;
               -  Implanted electrical stimulator (pace maker)&#xD;
&#xD;
               -  Metallic prosthesis or orthesis, cochlear implants&#xD;
&#xD;
               -  Intraocular foreign material&#xD;
&#xD;
               -  Pregnancy (on questioning)&#xD;
&#xD;
               -  Tutelage or any legal protection measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline TILIKETE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON</name>
      <address>
        <city>France</city>
        <state>Bron</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>optic neuritis</keyword>
  <keyword>vision</keyword>
  <keyword>quality of life</keyword>
  <keyword>pathophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

